Skip Navigation LinksHome > Published Ahead-of-Print > Adherence in the treatment of patients with extensively drug...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000221
Original Article: PDF Only

Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: A prospective cohort study.

O’Donnell, Max R. MD, MPH; Wolf, Allison MPH; Werner, Lise MSc; Horsburgh, C.Robert MD, MUS; Padayatchi, Nesri MBChB, MSc

Published Ahead-of-Print
Collapse Box


Objective: Extensively drug-resistant tuberculosis (XDR-TB)/HIV co-infection is difficult to treat with frequent adverse drug reactions, and high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug-resistance, and improve outcomes.

Methods: Prospective cohort study of XDR-TB patients on treatment in KwaZulu-Natal, South Africa. Adherence to ARV and TB medications was assessed separately at baseline and monthly. Knowledge, attitudes, and beliefs (KAB) were assessed at baseline. Optimal adherence was defined as self-report of taking all pills in the previous 7 days; missing any pills was defined as suboptimal adherence. Primary outcome was optimal adherence 6 months after initiation of XDR-TB treatment to TB medications, ARV, and both ('dual-adherence').

Results: 104 XDR-TB patients (79.8% HIV co-infected, 84.3% on ARV at enrollment) were enrolled and followed monthly (median 8 visits; IQR 4-12). Six-month optimal adherence was higher for ARV (88.2%) than TB medications (67.7%) (p<0.001). Low educational attainment, male gender, and year of enrollment were independently associated with dual suboptimal adherence. At baseline participants indicated that XDR-TB was curable (76.0%), HIV and TB were linked (81.7%), and ARV improves TB outcomes (72.1%). Baseline KAB did not predict subsequent adherence.

Conclusions: Medication adherence was significantly higher for ARV than for TB medications in this cohort. Short course treatment regimens for drug-resistant TB with lower pill burden may increase adherence and improve outcomes in XDR-TB/HIV. Programmatic support for dual-adherence is critical in the treatment of drug-resistant TB and HIV.

(C) 2014 by Lippincott Williams & Wilkins


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.